Compare CIF & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIF | EVAX |
|---|---|---|
| Founded | 1988 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 31.9M |
| IPO Year | N/A | 2020 |
| Metric | CIF | EVAX |
|---|---|---|
| Price | $1.62 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 64.6K | 30.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $1.42 |
| 52 Week High | $1.82 | $12.15 |
| Indicator | CIF | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 51.67 |
| Support Level | N/A | $2.70 |
| Resistance Level | $1.73 | $4.62 |
| Average True Range (ATR) | 0.02 | 0.33 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 18.18 | 54.80 |
Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.